HMHamish A. J. MacGregor

Hamish A. J. MacGregor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hamish A. J. MacGregor has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolutionary dynamics in the years preceding acute myeloid leukaemia

    by Caroline J. Watson, Gladys Y. P. Poon, Hamish A. J. MacGregor, Adriana V. A. Fonseca, Sophia Apostolidou, Aristi Damaskou, Christopher Boniface, Samuel Hackett, Aleksandra Gentry-Maharaj, Usha Menon, et al.

    Somatic evolution in ageing tissues underlies many cancers 1,2 . However, our quantitative understanding of the rules governing this pre-cancerous evolution remains incomplete. Here we exploit a unique collection of serial blood samples 3 , collected annually for up to a decade and beginning as early as 15 years before diagnosis of acute myeloid leukaemia, to provide a quantitative description of pre-cancerous evolutionary dynamics. Using deep duplex sequencing and evolutionary theory, we quantify the acquisition ages and fitness effects of the key driver events in acute myeloid leukaemia development. The first driver mutations are typically acquired in the first few decades of life, when the blood remains highly polyclonal. These early slow-growing clones subsequently acquire multiple further driver mutations that confer selective advantages up to 100-fold larger than the early drivers. These faster-growing clones harbouring multiple driver mutations can cause complete somatic sweeps of the blood decades before diagnosis, a feature strongly associated with future acute myeloid leukaemia. Our data show that the clonal dynamics of blood are consistent with a set of remarkably simple evolutionary rules that strike a balance between chance and determinism.

  • Open Access

    Shared inheritance reveals landscape of somatic and germline cancer risk in TP53

    by Hamish A.J. MacGregor, Jamie R. Blundell, Douglas F. Easton

  • Open Access

    No evidence of immunosurveillance in mutation-hotspot-driven clonal hematopoiesis

    by Barbara Walkowiak, Hamish A. J. MacGregor, Jamie R. Blundell

    The theory of immunosurveillance posits that T cells eliminate clones harboring nonself-antigens generated by somatic mutations. Although a role of immunosurveillance in cancer is supported by evidence, whether it affects precancerous expansions has not been well established. Here we studied the association between MHC–variant binding and risk of clonal hematopoiesis (CH), a blood precancer state, predicting MHC binding affinity toward CH hotspot variants in 380,000 UK Biobank participants and examining the relationship between predicted binding to each variant and its expansion risk. Despite the study being powered to detect subtle differences in selective pressure, we did not find associations between predicted binding and CH prevalence for any of the examined variants. In CH-affected individuals, we identified no relationship between predicted variant binding and clone size. Overall, we found no evidence that the MHC genotype affects which variants expand in CH, suggesting a limited role for immunosurveillance in shaping clonal expansions in the blood.


  • Open Access

    Shared inheritance reveals landscape of somatic and germline cancer risk in TP53

    by Hamish A J MacGregor, Jamie R Blundell, Douglas F Easton

    Pathogenic variants in TP53, the key tumour-suppressor gene underlying Li-Fraumeni syndrome (LFS), are among the best-established causes of inherited cancer predisposition. However, large-scale sequencing has revealed that many apparently pathogenic TP53 variants detected in blood are the result of somatic clonal expansions, complicating risk interpretation. Using blood-derived whole-exome data from 469,391 UK Biobank participants, we combined variant allele fraction (VAF) with haplotype-sharing analysis to distinguish germline and somatic TP53 variants. Germline variants were concentrated at sites linked to partial loss of p53 function and lower disease penetrance, whereas classic LFS alleles appeared almost entirely somatic. High-VAF carriers of classic LFS alleles conferred markedly increased risk of haematological malignancy but not solid tumours, consistent with large TP53-mutant clonal expansions. The prevalence of somatic clonal expansion also correlated with missense variant pathogenicity, suggesting that somatic activity provides an informative in vivo proxy for functional impact. These results provide new insights into TP53-associated cancer risk at the population level, demonstrate that somatic rather than germline risk predominates in middle-aged healthy adults and provide a scalable framework for variant classification in large-scale population genomics.